Accordingly, TMEM173 is consistent with immune activation phenotypes of DCs in B-ALL, suggesting that TMEM173 activation might be associated with enhanced anti-tumor functions of DCs. The gene discussed is STING1; the disease is precursor B-cell acute lymphoblastic leukemia.